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Abstract
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that in humans causes an acute febrile illness
characterized by fever, arthralgia, and rash. It is currently associated with large outbreaks in Asia, Africa, and
islands of the Indian Ocean and has been introduced from these tropical regions into Europe, where local
transmission has been recorded on two occasions. The underlying basis of the pathogenesis of CHIKV and
related alphaviruses that produce similar symptoms remains unclear. By applying new techniques, for example,
in vivo imaging in live animals and arthropods, we may improve our understanding of viral pathogenesis in
vertebrates and viral replication in mosquitoes. This technical report describes the evaluation of a CHIKV–
luciferase clone to visualize infection and dissemination in both Aedes aegypti and Aedes albopictus mosquitoes
and mice. In mosquitoes, luciferase activity was seen at 3 and 7 days post-infection in both head and abdomens.
In vivo imaging of CHIKV–luciferase was detected in mice for up to 5 days post-infection at the site of inocu-
lation with limited dissemination to the skeletal muscle.
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Introduction
Chikungunya virus (CHIKV) is a mosquito-borne al-phavirus, first isolated in Tanzania in 1952 (Robinson
1955). Human infections result in chikungunya fever
(CHIKF), an acute febrile illness characterized by fever, rash,
arthralgia, and in some patients, persistent and recurrent
arthritis-like symptoms lasting for months or occasionally
years (Tesh 1982; Powers and Logue 2007). CHIKV is endemic
in sub-Saharan Africa with a forest cycle of Aedes mosquitoes
and nonhuman primates but sometimes emerges to cause
large human outbreaks (Powers and Logue 2007). In South-
east Asia, CHIKV is also endemic and epidemic, but in this
region it apparently exists only in an urban cycle consisting of
humans and Aedes aegypti and Aedes albopictus mosquitoes
(Thiboutot et al. 2010). During the 2005–2006 epidemic, a viral
mutation enabled CHIKV to expand its vector host range by
increasing the viruses’ ability to infect Ae. albopictus mosqui-
toes (Tsetsarkin et al. 2007). There have been numerous cases
of importation of CHIKF into nonendemic countries, and in
September of 2010, cases of CHIKF in France occurred in
patients with no travel history, indicating possible local
transmission (Gould et al. 2010). This is the second time that
CHIKV has been transmitted locally in Europe, the first being
in Italy in 2007 (Enserink 2007, Rezza et al. 2007).
The potential for CHIKV to become a global health prob-
lem causing disease in both tropical and subtropical areas has
prompted new research interest on therapeutics and vac-
cines. The pathogenesis of CHIKV in humans is not fully
understood, although recent work with animal models has
provided evidence of an immune-mediated pathology that
results in myositis in skeletal muscles (Gardner et al. 2010,
Higgs and Ziegler 2010). Experimental studies using an
outbred mouse model in which animals develop an acute
viremia and severe myositis in the skeletal muscle (Ziegler
et al. 2008) have demonstrated a differential effect on mouse
cytokine responses to CHIKV infection when CHIKV is de-
livered with mosquito saliva (Thangamani et al. 2010). The
need to have a better understanding of viral replication in
animals and mosquitoes has prompted the development of
CHIKV infectious clones (ICs) that contain reporter gene se-
quences (Tsetsarkin et al. 2006). In this report, we describe the
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construction of the first CHIKV–luciferase IC and the char-
acterization of this clone in both mosquitoes and mice. This
recombinant genome was infectious for Aedes mosquitoes
when orally presented and allowed for visual evaluation of
midgut infection and dissemination to secondary tissues in
the vector. Further, post-infection in vivo imaging of the sites
of viral replication was conducted in mice that demonstrated
CHIKV replication at the site of infection for up to 5 days
post-inoculation.
Materials and Methods
Construction of CHIKV–luciferase IC
A humanized Renilla luciferase reporter gene, derived
from phRL-TK (Promega Corporation, Madison, WI), was
cloned into a CHIKV IC in a 5’ orientation relative to the
structural cassette (Fig. 1). Briefly, an intermediate cloning
construct was generated by first cloning the Renilla luciferase
gene into a Sindbis virus (SINV) replicon via blunt-end liga-
tion of cloning fragments following restriction endonuclease
digestion and T4 polymerase treatment (New England Bio-
labs, Ipswich, MA) of phRL-TK and pSinRep5 (Invitrogen,
Carlsbad, CA). This intermediate construct designated p356.2
was generated to flank the luciferase gene with convenient
restriction sites to facilitate ease of insertion into pCHIK-LR-
5’-GFP (Tsetsarkin et al. 2006). The enhanced green fluores-
cent protein gene in the plasmid construct pCHIK-LR-5’-GFP
was then replaced with the Renilla luciferase gene derived
from p356.2 to generate pCHIK-LR-5’–Luciferse (CHIKV-
LUC). All intermediate and final constructs were verified by
sequence analysis. In vitro transcribed RNAs derived from
this recombinant genome were generated using the mMes-
sage mMachine kit (Ambion, Austin, TX), directly electro-
porated into BHK-21 cells, and harvested and aliquoted
on day 2 post-electroporation. Aliquoted virus was stored at
- 80C for use in these experiments. The titer of the stock virus
was 106.5 tissue culture infectious dose50 (TCID50)/mL.
In vitro infections and luciferase imaging
Vero cells were grown at 37C with 5% carbon dioxide in
minimum essential medium, supplemented with 5% fetal bo-
vine serum (FBS), 2% sodium bicarbonate, 2 mM l-glutamine,
and 1% penicillin–streptomycin (Invitrogen). C6/36 cells (Ae.
albopictus) were grown at 27C in L15 media (Invitrogen)
supplemented with 10% tryptose phosphate broth solution
(Sigma-Aldrich, St. Louis, MO), 10% FBS, 1% penicillin–
streptomycin, and 2 mM l-glutamine (Invitrogen). For in vitro
studies of CHIKV-LUC, a six-well tissue culture plate was
seeded with C6/36 cells or Vero cells, and 48 h later, when
cells reached confluence, they were infected with CHIKV-
LUC at a concentration of 104.5 TCID50. Briefly, 100 lL of viral
stock was added to each well and was allowed to incubate for
1 h at 27C (C6/36) or 37C (Vero cells). After incubation, the
appropriate medium was added to each well. Cells were
imaged in the six-well plate at 24 h post-infection (hpi). The
cell culture plate was placed in a Xenogen In Vivo Imaging
System (IVIS) 200 Series (Caliper Life Sciences, Hopkinton,
MA) and images were immediately recorded before and after
addition of the ViviRen substrate (Promega Corporation).
Prior to substrate addition, cell medium was removed and
fresh medium was added. ViviRen was dissolved in dimethyl
sulfoxide (DMSO), diluted in phosphate-buffered saline (PBS)
with 10% FBS, and added to the tissue culture plate wells to a
final concentration of approximately 1–0.1 nM. An exposure
time of 1 s was used to visualize luciferase expression in cell
culture.
Mosquito infections and luciferase imaging
Ae. aegypti (Rexville D strain Higgs white-eye) and
Ae. albopictus (Galveston) mosquitoes were reared at 27C
and a relative humidity of 80% under a 16-h light:8-h dark
photoperiod, as previously described (Higgs 2004). Four to 6
days post-eclosion, female mosquitoes were fed an artificial
blood meal using the Hemotek feeding system (Discovery
Workshops, Accrington, United Kingdom) in an isolation
glove box located in a Arthropod Containment Level 3
insectary. A 1:1 mixture of defibrillated sheep’s blood (Col-
orado Serum Company, Boulder, CO) and virus stock, for a
final titer of 104.5 TCID50/mL of CHIKV-LUC, was heated to
37C and placed in the Hemotek feeder, and the membrane
was placed on the mosquito containers. After feeding,
mosquitoes were sorted, and fully engorged mosquitoes
were transferred to an environmental chamber at 27C and
supplied with 10% sucrose ad libitum (Higgs 2004). At 3 and
7 days post-infection (dpi), mosquitoes were chilled and legs
and wings were removed. A stock solution of the substrate
ViviRen (0.24 mM) was intrathoracically inoculated to vi-
sualize the luciferase expression from the CHIK-LUC infec-
tion. Mosquitoes were placed into a six-well plate and
visualized using a Xenogen IVIS instrument located in a
biosafety level-3 laboratory. An exposure time of 5 s was
used and images were taken 30–40 min following injection of
substrate.
CHIKV-LUC infection and visualization in mice
Weaning (3–4 week old) CD-1 mice (Charles River La-
boratories, Wilmington, MA) were housed in an animal bio-
safety level-3 facility and all manipulations were performed in
accordance with NIH, AAALAC, and UTMB standards for
animal care and infection. Mice were anesthetized and virus
was injected in the right rear footpad with 105.5 TCID50 of
CHIKV-LUC in a total volume of 0.04 mL in PBS. At 12, 24, 48,
72, and 96 h and 5 dpi, mice were anesthetized and injected
FIG. 1. Gene map of chikungunya virus–luciferase (CHIKV-LUC).
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with the ViviRen substrate. The substrate was first dissolved
in DMSO (0.37 mg in 10 lL of DMSO) and diluted in PBS with
10% FBS to a final concentration of 0.236 mM. Immediately
prior to substrate injection, IVIS images of the mice were taken
to confirm the lack of autofluorescence. ViviRen substrate was
injected into each mouse in a final volume of 50 lL at a dose of
approximately 1 mg/kg (Otto-Duessel et al. 2006). Im-
mediately after substrate addition, mice were returned to the
IVIS chamber and were imaged every minute for time course
studies. For later experiments, the substrate was allowed to
diffuse in the mice for 20 min before images were taken. This
time point was chosen as it corresponds to the peak of lumi-
nescence in the mice. CHIKV 5’ GFP, described previously
(Tsetsarkin et al. 2006), was used as a negative control and
injected at the same concentration and location as the CHIKV-
LUC. The exposure time for the images was 30 s and region of
interest calculations were made using the IVIS Living Image
Software (Caliper Life Sciences).
Results
Cell culture
Infectious CHIKV-LUC virus caused luminescence and
cytopathic effect in cultures of Vero cells at 24 and 48 hpi.
Virus derived from the CHIKV-LUC construct replicated with
similar kinetics to wild-type virus, with maximum titers of
approximately 106.5 TCID50/mL 48 hpi. Luminescence was
measured at both 24 and 48 hpi with the IVIS machine and
signal was detected. To optimize the substrate concentration
for detection in vitro, Vero and C6/36 cells were plated into
six-well dishes and were infected with CHIKV-LUC at a
concentration of 104.5 TCID50 (Fig. 2). At 24 hpi, ViviRen
FIG. 2. C6/36 cells infected with CHIKV-LUC and imaged with ViviRen substrate added at 24 h post-infection. Cells were
infected 24 h prior to addition of substrate. Well 1: control phosphate-buffered saline; wells 2–6: infected with CHIKV-LUC;
wells 1 and 6: 1 nM ViviRen; well 2: no VivRen; well 3: 0.1 nM ViviRen; well 4: 0.25 nM ViviRen; well 5: 0.75 nM ViviRen.
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substrate was titrated (1–0.1 nM of ViviRen) on a series of
infected monolayers; ViviRen-treated uninfected cells and
substrate-negative CHIKV-LUC–infected cells were also in-
cluded as controls. Similar luciferase activity was detected in
both Vero and C6/36 cells. Luciferase activity was observed
in a dose-dependent manner over the substrate concentra-
tions evaluated, with peak luminescence counts being an
average of 2590 for C6/36 cells and 2030 for Vero cells (Fig. 3).
No luminescence was observed in virus- or substrate-negative
controls.
Imaging of Aedes mosquitoes
Ae. albopictus and Ae. aegypti are the principle vectors of
CHIKV in the urban setting. To understand the rates of in-
fection and dissemination, the CHIKV-LUC virus was used to
visualize whole mosquitoes after being fed an artificial blood
meal containing CHIKV-LUC. Imaging was performed on
live mosquitoes following removal of legs and wings. It was
observed that both Ae. albopictus and Ae. aegypti were sus-
ceptible to infection by the CHIKV-LUC and evidence of in-
fection was observed as early as 3 dpi, with abdominal,
thoracic, and head infection being detected by 7 dpi, whereas
no intrinsic luminescence was observed in uninfected controls
(Fig. 4). At 3 dpi, luminescence, indicative of CHIKV-LUC
viral replication, was observed in 5 of 9 Ae. aegypti and 8 of 9
Ae. albopictus (Table 1). By visual examination, head or ab-
dominal luminescence could be distinguished, but abdomi-
nal luminescence could not be further distinguished from
that of the midgut or other parts of the abdomen. At 3 dpi,
three Ae. albopictus had a disseminated infection, which in-
cluded the whole body of the mosquito, and in five mos-
quitoes, luminescence was restricted to the midgut. At 7 dpi,
23 of 24 Ae. aegypti showed luminescence, with 15 mosquitoes
displaying a disseminated infection pattern involving both
the head and abdomen, 6 with only an abdominal infection,
and 2 with only head infections. These data suggest that
during the course of infection/dissemination, the extent/
intensity of midgut infection may have declined over time. In
Ae. albopictus mosquitoes at 7 dpi, 10 of 15 mosquitoes were
infected, with 2 having a disseminated infection and 8 having
only an abdominal infection. At 3 dpi, Ae. albopictus mos-
quitoes had a higher rate of infection when compared with
Ae. aegypti mosquitoes, but at 7 dpi Ae. aegypti mosquitoes
were more easily infected with CHIKV-LUC.
In vivo imaging in mice
A mouse model of CHIKF has been developed to study the
pathogenesis of CHIKV (Ziegler et al. 2008). To have a better
understanding of the areas of viral replication in the mice,
CHIKV-LUC was evaluated in this mouse model. First, it was
important to determine the bioavailability of the ViviRen
substrate and to optimize the delivery of the substrate. To do
this, different time course studies and injection schemes were
evaluated, including intraperitoneal (IP) and subcutaneous
(SC) delivery methods. Intrinsic luminescence of the substrate
was observed in control mice at the inoculation site (data not
shown). To minimize this effect, ViviRen substrate was in-
jected in the scruff of the neck, resulting in only minor intrinsic
luminescence in the neck scruff. It was also observed that
luminescence was visible for up to an hour after injection, but
was completely undetectable by 12 hpi. Maximum lumines-
cence was observed by 20 min post-ViviRen injection when
delivered either IP or SC and began to decrease thereafter
(Fig. 5). Local replication of CHIKV-LUC was observed in
mice as early as 12 hpi and up to 7 dpi (Fig. 6). Dissemination
was observed only in one mouse, which resulted in hind limb
muscle infection. This began at 3 dpi and remained visible up
to 5 dpi. It is possible that there was more dissemination in the
mice, but that either it was in a deep tissue that could not be
visualized or it was diffuse and did not result in a strong
enough signal to be detected. SC infection of CHIKV-LUC in
mice resulted in local replication for 2 days, but no signal was
observed (data not shown). As previous works in the labo-
ratory have shown that SC infection of CHIKV results in a
disseminated disease, it is unclear why no luciferase activity
was seen in these mice.
Discussion
In vivo imaging in whole animals is gaining acceptance in
the field of infectious diseases. With the ability of this tech-
nology to be utilized in biocontainment laboratories, real-time
knowledge of the pathology of highly pathogenic agents can
be obtained using fewer animals. Limited published work of
viral luciferase ICs exists for a comparison of these studies.
Cook and Griffin (2003) conducted a similar study with SINV
using IVIS imaging. The alphavirus, SINV, induces very dif-
ferent pathology in mice, causing neurological disease and
limited mortality. Intranasal inoculation of SINV–luciferase
clones in mice resulted in visualization of viral replication in
the brain and neurons. This work affirmed the previous
work with SINV. CHIKV infection has been shown to cause
very little neurological disease when subcutaneously inocu-
lated (Ziegler et al. 2008, Gardner et al. 2010, Morrison et al.
2011). Intranasal inoculation of CHIKV in mice has been
shown to cause neuronal changes (Powers and Logue 2007,
Wang et al. 2008). It is not surprising that neuronal involve-
ment was not observed in the CHIKV-LUC–infected mice. If
FIG. 3. Dose-dependent luminescence of in vitro luciferase
activity in Vero and C6/36 cells. Cells were infected with
CHIKV-LUC, and at 24 hpi, ViviRen substrate was added in
the concentrations indicated. Luminescence was measured
using the IVIS machine and average luminescence per well
was calculated.
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this experiment is repeated using an intranasal inoculation of
CHIKV, albeit an unnatural route of CHIKV exposure, results
similar to the previous SINV work might be expected. Other
studies both with intra-cerebral and subcutaneous infection of
luciferase tagged Sindbis virus showed dissemination to
peripheral tissues that was age and heparin sulfate dependent
in mice using IVIS technology at time points less than 24 hours
post infection and 72 hours post infection (Ryman 2007a,
Ryman 2007b). Work with both Eastern and Venezuelan
equine encephalitis using luciferase encoding genomes and
foot pad inoculations had very similar results as we have
shown with CHIKV (Gardner 2008). While Venezuelan
equine encephalitis virus disseminated out of the footpad to
the draining lymph node, Eastern equine encephalitis virus
did not. These reports further support our work with CHIKV
and how it relates to other alphaviruses.
IVIS imaging in live mice has been also highly utilized in
malaria and cancer research. Using reporter genes in malaria
parasites has allowed researchers to visualize parasite load in
both mosquito and mouse hosts. Luciferase-tagged parasites
have been visualized in mouse liver using in vivo imaging and
the parasite number calculated using IVIS has been correlated
with the results of qRT–polymerase chain reaction analysis
(Ploemen et al. 2009). In vivo imaging using microscopy has
been also used to visualize GFP-tagged malaria parasites in
the salivary glands of infected mosquitoes (Heussler and
Doerig 2006). Tumors expressing a wide number of reporter
genes have been used in combination with the IVIS to track
the growth of tumors and their response to various treatments
(Choy et al. 2003, Otto-Duessel et al. 2006).
Although GFP CHIKV clones are useful in mosquitoes,
their ability to be effective reporters in mice in the IVIS system
is limited because of intrinsic fluorescence of the mouse skin
and fur, which results in a low signal-to-noise ratio. When
working with luciferase constructs, there are a number of
enzyme/substrate combinations that can be used. The Renilla
luciferase enzyme has many features that make it a better
choice when compared with other luciferase systems,
including that it is independent of intracellular ATP, it is not
secreted from the cell, and the coding region is small (Ki-
mura et al. 2010). The use of the humanized Promega hRluc
gene has increased luciferase expression in mammalian cells
(Zhuang et al. 2001). In this report, we used the ViviRen
substrate paired with a humanized Renilla luciferase en-
zyme, because recent reports showed the high bioavailabil-
ity of this substrate compared with other coelenterazine
anologs (Otto-Duessel et al. 2006). With further optimiza-
tion, IVIS imaging using the CHIKV-LUC–infected mice
FIG. 4. IVIS images of Ae. aegypti and Ae. albopictus following oral infection of CHIKV-LUC. Aedes aegypti and Aedes
albopictus exhibited luciferase activity after infection with an artificial blood meal and injection of ViviRen. Mosquitoes were
injected with ViviRen substrate at 3 or 7 days p.i. Images are a composite of individuals that represent the progression of
infection in both Ae. aegypti (A) and Ae. albopictus (B). Uninfected mosquitoes injected with ViviRen substrate exhibited no
luminescence and are the first mosquitoes in each panel. p.i., post-infection.
Table 1. Mosquito Oral Infection and Dissemination
Mosquito species Day 3 p.i Day 7 p.i
Aedes aegypti
Midgut only 5/5 (100%) 6/23 (26.1%)
Disseminated 0/5 17/23 (73.9%)
Total 5/9 (55.6%) 23/24 (95.8%)
Aedes albopictus
Midgut only 5/8 (62.5%) 8/10 (80%)
Disseminated 3/8 (37.5%) 2/10 (20%)
Total 8/9 (88.9%) 10/15 (66.7%)
Comparison of Ae. aegypti and Ae. albopictus midgut infection and
dissemination rates at 3 and 7 days postfeeding on a blood meal
containing chikungunya virus–luciferase. At 30–40 min prior to
imaging, ViviRen substrate was injected into the abdomen of the
mosquito, and then infection and dissemination were quantified
using the IVIS on whole live mosquitoes in six-well dishes. Images
were rendered using the Living Image software.
FIG. 5. Luminescence intensity in murine hosts relative to
time post-ViviRen injection, with the luminescence as a fac-
tor of time and injection location. Mice were injected with
substrate either sub-cutaneously (SC) or intra-peritoneally
(IP) and imaged approximately every 90 s.
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may allow us to visualize deeper tissues and help describe
the progress of pathogenesis of CHIKV infections.
This is the first report of using IVIS system to screen mos-
quitoes infected with CHIKV. The application of this tech-
nology in this way would allow for quick screening of
mosquitoes that are still alive. In this report, we show that
CHIKV-LUC was able to infect and disseminate in both
Ae. aegypti and Ae. albopictus mosquitoes. Disseminated
infection was defined as mosquitoes that showed lumines-
cence activity in the head region. It is important to note that
luminescence in the abdominal region could be from tissues
outside of the midgut. Unfortunately, the legs and wings of
the mosquitoes were not imaged with the whole mosquitoes.
Using IVIS, we are quickly able to determine infection and
dissemination rates in mosquitoes that would previously re-
quire labor- and time-intensive homogenization and titration.
As the mosquitoes are still alive, we would also have the
capability to take the mosquitoes and express saliva from
them or select individual mosquitoes for further studies. This
technology could be easily applied to other alphaviruses for
understanding of their interaction with mosquito hosts. The
ability to visually differentiate between infected and unin-
fected mosquitoes, whilst still alive, could greatly increase the
efficiency of mosquito work and opens up the possibility to do
FIG. 6. IVIS images of mice infected with CHIKV-5’-LUC. Luciferase activity was observed as early as 12 h post-infection
and up to 5 days post-infection. Pictures were taken at 20 min after injection of the substrate in accordance with peak
luminescence intensity. The mouse pictured on the left on each panel was infected with CHIKV-GFP, but also received
ViviRen at 20 min prior to imaging. Mice were imaged at 12 h (A), 24 h (B), 48 h (C), 72 h (D), 96 h (E), and 5 days (F) after
inoculation of CHIKV-LUC in the right rear foot pad.
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specific labor-intensive studies on a specific subset of infected
mosquitoes.
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